Suppr超能文献

基于高效液相色谱、网络药理学、分子对接和细胞因子验证的阿胶四物汤治疗原发性免疫性血小板减少症的机制及分子靶点

Mechanism and Molecular Targets of Ejiao Siwu Decoction for Treating Primary Immune Thrombocytopenia Based on High-Performance Liquid Chromatograph, Network Pharmacology, Molecular Docking and Cytokines Validation.

作者信息

Wang Ming Jing, Sun Yan, Song Ying, Ma Ju Ning, Wang Zi Qing, Ding Xiao Qing, Chen Hai Yan, Zhang Xue Bin, Song Min Min, Hu Xiao Mei

机构信息

Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.

出版信息

Front Med (Lausanne). 2022 Jul 13;9:891230. doi: 10.3389/fmed.2022.891230. eCollection 2022.

Abstract

We explored the mechanisms and molecular targets of Ejiao Siwu Decoction (EJSW) for treating primary immune thrombocytopenia (ITP) using network pharmacology and molecular docking. Active compounds of EJSW were identified by high-performance liquid chromatography-diode array detector (HPLC-DAD) and high-performance liquid chromatography-mass spectrometry (HPLC-MS) and their targets were obtained from HERB and SwissTargetPrediction, and ITP targets were obtained from Comparative Toxicogenomics Database (CTD) and GeneCards. STRING and Cytoscape were used for protein-protein interaction (PPI) network analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses by WebGestalt yielded a gene-pathway network, Autodock molecular docking was applied to screen targets and active compounds, and cytokines were detected using a cytometric bead array (CBA) human inflammation kit. We identified 14 compounds and 129 targets, and 1,726 ITP targets. RAC-alpha serine/threonine-protein kinase (AKT1), tumour necrosis factor (TNF), interleukin-6 (IL6), caspase-3 (CASP3) and tumour suppressor protein (TP53) were core targets (nodes and edges). Functional annotation identified cofactor binding and coenzyme binding, and 20 significantly enriched pathways. Active compounds of EJSW were successfully docked with ITP targets. Tumour necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β) were upregulated in ITP patients, vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth factor D (VEGF-D) were downregulated, and EJSW treatment reversed these trends. EJSW may regulate key ITP targets based on the analyses, and protect vascular integrity through AGE-RAGE signalling, complement and coagulation cascades, and VEGF signalling by downregulating TNF-α, IL-1β and other inflammatory factors.

摘要

我们运用网络药理学和分子对接技术,探索了阿胶四物汤(EJSW)治疗原发性免疫性血小板减少症(ITP)的机制及分子靶点。通过高效液相色谱-二极管阵列检测器(HPLC-DAD)和高效液相色谱-质谱联用仪(HPLC-MS)鉴定出EJSW的活性成分,其靶点从中药系统药理学数据库(HERB)和瑞士药物靶点预测数据库(SwissTargetPrediction)获取,而ITP靶点则从比较毒理基因组学数据库(CTD)和基因卡片数据库(GeneCards)获取。利用STRING和Cytoscape软件进行蛋白质-蛋白质相互作用(PPI)网络分析。通过WebGestalt进行基因本体论(GO)和京都基因与基因组百科全书(KEGG)分析,得出基因-通路网络,应用Autodock分子对接技术筛选靶点和活性成分,并使用细胞计数珠阵列(CBA)人炎症检测试剂盒检测细胞因子。我们鉴定出14种化合物和129个靶点,以及1726个ITP靶点。RAC-α丝氨酸/苏氨酸蛋白激酶(AKT1)、肿瘤坏死因子(TNF)、白细胞介素-6(IL6)、半胱天冬酶-3(CASP3)和肿瘤抑制蛋白(TP53)是核心靶点(节点和边)。功能注释确定了辅因子结合和辅酶结合,以及20条显著富集的通路。EJSW的活性成分成功与ITP靶点对接。ITP患者中肿瘤坏死因子α(TNF-α)和白细胞介素-1β(IL-1β)上调,血管内皮生长因子A(VEGF-A)和血管内皮生长因子D(VEGF-D)下调,而EJSW治疗逆转了这些趋势。基于这些分析,EJSW可能调节ITP关键靶点,并通过下调TNF-α、IL-1β和其他炎症因子,经由晚期糖基化终末产物受体(AGE-RAGE)信号通路、补体和凝血级联反应以及VEGF信号通路保护血管完整性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bff/9326259/5298b21ba290/fmed-09-891230-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验